- Home
- VYGR
as 10-07-2025 3:30pm EST
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 231.9M | IPO Year: | 2015 |
| Target Price: | $16.71 | AVG Volume (30 days): | 789.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.65 - $8.28 | Next Earning Date: | 11-11-2025 |
| Revenue: | $42,580,000 | Revenue Growth: | -70.38% |
| Revenue Growth (this year): | -61.65% | Revenue Growth (next year): | 107.10% |
Stock Insider Trading Activity of Voyager Therapeutics Inc. (VYGR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ferguson Toby | VYGR | Chief Medical Officer | Aug 18 '25 | Sell | $3.73 | 19,000 | $70,870.00 | 138,914 |
Latest Voyager Therapeutics Inc. News
VYGR Breaking Stock News: Dive into VYGR Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
Sector Update: Health Care Stocks Climb Late Afternoon
MT Newswires
3 months ago
Sector Update: Health Care
MT Newswires
3 months ago
Voyager Therapeutics Introduces New Program Targeting Genetic Risk Factor of Alzheimer's Disease
GlobeNewswire
3 months ago
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
GlobeNewswire
4 months ago
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
TipRanks
4 months ago
Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks
Simply Wall St.
5 months ago
With 46% ownership, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has piqued the interest of institutional investors
GlobeNewswire
5 months ago
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
Compare VYGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYGR Voyager Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.